Background: Intraocular pressure (IOP) rise is the most common complication of Nd YAG laser posterior capsulotomy, and the aim of this study was to compare the effect of oral acetazolamide versus topical Co-biosopt in preventing IOP rise following Nd YAG laser posterior capsulotomy.

Materials and Methods: This clinical trial was done on 200 patients who underwent laser Nd: YAG capsulotomy. First group received oral acetazolamide 250 mg q 6h and placebo drops q 8h and second group received Co-biosopt) timolol 0/5% and dorzolamide 2%) drops q 8h and oral placebo capsule q 6h. IOP was measured before and 24 hours after laser capsulotomy.

Results: Mean IOP of right and left eye 24 hours after capsulotomy in the acetazolamide group was significantly decreased as compared to the previous (p=0.001) and in Co-Biosopt group the values 24 hours after capsulotomy was significantly decreased as compared with the previous in right and left eye (p=0.001).

Conclusion: According to oral acetazolamide side effects and desirable IOP reduction with Co-Biosopt that recently entered to Iran’s market and have typical domestic, this medication can be an option for preventing IOP rise after laser capsulotomy in a patient with posterior capsular opacification.

Background: Glaucoma is the second most common cause of blindness and it is one of the main causes of irreversible blindness. Multi-drug regimens usually recommended in reducing intraocular pressure (IOP) in patients with glaucoma. This study was aimed to compare the effect of combination therapy with Timolol and Latanoprost vs. Timolol and Dorzolamide in reducing IOP in patients with open-angle glaucoma.

Materials and Methods: In this blind randomized clinical trial study, 60 eyes with glaucoma were randomly assigned to two treatment groups including Timolol and Latanoprost vs. Timolol and Dorzolamide. Required variables were measured before and 6 weeks after the intervention. The data was analyzed by running the Stata software (version 12) at a significance level of 0.05.

Results: The mean age in groups of Timolol-Latanoprost and Timolol and Dorzolamide was 72.6 and 67.6 years old, respectively. Analysis of the data revealed that there was no significant difference between groups in terms of intraocular pressure (IOP), visual acuity and cup to disc ratio.

Conclusion: According to our findings, there were no statistical significant differences in the IOP lowering effect between both treatments in open angle glaucoma patients.